Adare Pharmaceuticals was formerly called Aptalis Pharmatech until 2015 when it was aquired by global investment firm, TPG. Adare Pharmaceuticals utilizes its Pharmaceutical Technology and Microbiome scientific platforms to develop novel products. Adare provides co-development and contract services to biopharmaceutical companies to develop and manufacture products that are marketed by its partners. Through its Adare Development affiliate, Adare invests in its own product pipeline. Products developed and manufactured by Adare include LacteolTM, ZoolacTM, ViactivTM, Amrix ® as well as branded and complex generic products.
Lacteol is a proprietary combination of Lactobacillus fermentum and Lactobacillus delbrueckii and fermented culture medium. In addition to rehydration and dietary measures the product is used as a supplemental treatment for diarrhea in adults and children. The company develops products in therapeutic categories of cardiovascular, pain management, GI and CNS as well as taste management an oral disintegration of tablets.
In March 2019, Adare Pharmaceuticals (Adare) announced positive results from its Phase IIb study (FLUTETM) for one of its rare disease investigational products, APT-1011 (AdvaTab® Fluticasone) for Eosinophilic Esophagitis (EoE). Eosinophilic Esophagitis (EoE) is a chronic, allergic inflammatory disease. The disease is characterized by eosinophilic infiltration of the esophagus which can put patients at risk for food imaction due to inflammation and development of strictures and narrowing of the esophagus. APT-1011 is a novel formulation incorporating Adare's proprietary AdvaTab® technology is a fluticasone product. Fluticasone is a corticosteroid treatment that reduces swelling or inflammation in the nasal passages. APT-1011 is an oral formulation of fluticasone that allows topical delivery to the esophagus and minimizes time in the oral cavity. At the time of this announcement there were no FDA approved EoE treatments available in the US.EoE treatments include food elimination diets, off-label use of proton pump inhibitors and glucocorticoid steroid formulations.
The Adare Pharmaceuticals HARMONY Clinical Trial program includes the FLUTE study which is focused on the development of APT-1011 in eosinophilic esophagitis (EoE) in adults, adolescents and children. APT-1011 has previously been shown to be effective in reducing esophageal eosinophil counts and endoscopic findings in adults with a diagnosis of EoE. The FDA and EMA have given APT-1011 orphan drug designation.
Dr. Peter C. Richardson M.D.
Chief Medical Officer and Vice President of Research & Development
Mr. Daniel Bélanger
Vice President of Human Resources
Mr. John J. Fraher
Chief Executive Officer and President
Mr. Joseph A. Del Buono
Chief Financial Officer and Vice President of Finance